Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
The purpose of this study is to continue to assess safety and tolerability, and to allow continued access to study treatment for subjects already receiving spartalizumab as single agent or in combination with other study treatments.
Advanced Solid Tumors
DRUG: PDR001
Frequency and nature of AE and SAE by subject, Safety data., 5 years|Number of subjects with PDR001 dose interruption and/or reduction, 5 years
Number of subjects receiving PDR001, 5 years|Subject's exposure duration, 5 years
The purpose of this study is to continue to assess safety and tolerability, and to allow continued access to study treatment for subjects already receiving spartalizumab as single agent or in combination with other study treatments.